Gyokikai Medical Corporation;Human Metabolome Technologies, Inc.
发明人:
申请号：
EP15844112.1
公开号：
EP3190413A1
申请日:
2015.09.24
申请国别(地区):
EP
年份:
2017
代理人:
摘要：
[Problem]To provide a method in which a phosphoethanolamine (PEA), which is a biomarker of depression, is directly linked to treatment.[Solution]A method for predicting options of depression treatment drugs of the present invention comprises the following steps:(1) measuring a PEA level in blood collected from a patient suspected of depression；(2) measuring whether the blood PEA level of the patient is lower than a reference value or not, wherein if the measured value of the patient is lower than values of healthy persons, the patient suffers from depression exhibiting a decreased PEA level as an indicator； and(3) predicting options of depression treatment drugs on the basis of the presence or absence of decreased blood PEA level in the patient.
